Fetal stem cells are used primarily in experimental treatments for neurological conditions, spinal cord injuries, blood disorders, and birth defects, though most applications remain in clinical trials rather than routine medical practice. These cells, collected from sources like amniotic fluid, placental tissue, and umbilical cord blood, occupy a unique middle ground between embryonic and adult stem cells, offering flexibility without some of the ethical and safety concerns tied to embryonic lines.
Where Fetal Stem Cells Come From
The term “fetal stem cells” covers cells drawn from several sources during or after pregnancy. Amniotic fluid is one of the most accessible. It can be collected through amniocentesis, a routine prenatal procedure that poses minimal risk to mother or fetus, and the fluid is also routinely discarded after birth. Placental tissue, umbilical cord blood, and (more controversially) tissue from elective abortions are other sources.
Amniotic fluid stem cells have attracted particular interest because they avoid two major problems. Unlike embryonic stem cells, they don’t form tumors after transplantation. And unlike adult stem cells harvested from bone marrow, collecting them doesn’t require an invasive procedure on a patient. These cells can differentiate into multiple tissue types, including bone, muscle, nerve, and fat cells, making them versatile raw material for regenerative medicine.
Spinal Cord Injury Repair
One of the most promising applications is in spinal cord injury, where damaged nerve tissue has historically been considered irreparable. A meta-analysis covering 30 studies and 656 patients found that stem cell transplantation led to measurable improvement in 43.3% of patients on overall injury scores, 49.4% in motor function, and 73.6% in sensory function. The side effect profile was relatively mild and transient. Most of these studies used mesenchymal stem cells, a type found abundantly in fetal and placental tissue, though some used embryonic-derived cells.
The sensory improvements are particularly notable. Nearly three out of four patients regained some sensation, which can make a meaningful difference in daily life even when full mobility doesn’t return. Motor recovery, while more modest, still occurred in roughly half of patients studied.
Neurological Conditions
Fetal neural stem cells have been tested in Parkinson’s disease, where the goal is to replace the dopamine-producing brain cells that die off as the disease progresses. Two randomized controlled trials, involving 74 people with advanced Parkinson’s, compared fetal cell transplants to sham surgery. The results were inconclusive. Neither trial demonstrated clear superiority over sham surgery in motor scores or daily functioning at one to two years of follow-up. Larger trials are underway to provide more definitive answers.
In Alzheimer’s disease research, fetal-derived placental cells have shown long-term benefits in animal models. Rather than replacing damaged neurons directly, these cells appear to work by resetting parts of the immune system and releasing enzymes that break down the toxic protein plaques characteristic of Alzheimer’s. This points to a broader theme in fetal stem cell research: these cells often help not by becoming new tissue themselves, but by coaching the body’s own repair systems.
How Fetal Stem Cells Promote Healing
Much of the therapeutic value of fetal stem cells comes from what they release rather than what they become. These cells secrete a cocktail of signaling molecules that stimulate blood vessel growth, reduce inflammation, and activate the body’s own repair processes. Placental stem cells, for instance, produce high levels of molecules that promote new blood vessel formation, encourage tissue growth, and regulate inflammation. Cord blood stem cells release compounds that stimulate skin cell growth and migration, which is why they’ve been studied for wound healing.
Amniotic fluid stem cells produce their own potent mix of repair signals. In wound healing studies, their secretions activated skin cells called fibroblasts, the cells responsible for building new connective tissue. When researchers applied just the liquid these stem cells had been grown in (without the cells themselves), it still accelerated wound repair. This suggests that for some applications, the cells’ secretions alone could be therapeutic, potentially simplifying treatment.
Umbilical cord stem cells are particularly rich in molecules that protect and regenerate nerve tissue. They produce compounds that support the survival of brain cells in the hippocampus, a region critical for memory, and promote both nerve growth and new blood vessel formation at injury sites.
Treating Birth Defects Before Birth
One of the most groundbreaking recent applications involves treating spina bifida while the baby is still in the womb. A UC Davis Health research team performed the world’s first combination of fetal surgery with placenta-derived stem cells to repair the spinal defect in utero. The Phase 1 trial, called the CuRe Trial, demonstrated strong enough safety results that the FDA and an independent monitoring board approved advancing to Phase 1/2a, which is now enrolling up to 35 patients.
This approach adds a layer of stem cells during the standard fetal surgery that closes the spinal opening. The idea is that the stem cells will enhance nerve repair beyond what surgery alone achieves, potentially reducing the lifelong disabilities associated with spina bifida.
Blood Disorders and In-Utero Transplants
Transplanting blood-forming (hematopoietic) stem cells into a fetus before birth has been attempted for conditions like severe combined immunodeficiency, thalassemia, and other inherited blood disorders. The logic is compelling: a fetus’s immature immune system should be less likely to reject donor cells. In practice, results have been mixed. Among 46 reported cases, successful engraftment occurred only in babies with severe combined immunodeficiency, a condition where the fetus essentially lacks an immune system to mount a rejection.
For other blood disorders like thalassemia, the transplanted cells failed to establish themselves in meaningful numbers. In one case of beta-thalassemia, a fetus-to-fetus transplant performed between 14 and 20 weeks of gestation actually triggered an immune response against the donor cells. This was a surprising finding, since it was widely assumed that fetuses at that stage wouldn’t mount such a reaction. The challenge of achieving useful engraftment in non-immunodeficiency disorders remains unsolved.
Diabetes Research
Fetal pancreatic cells have shown promise as a source of insulin-producing cells. Researchers have successfully coaxed fetal pancreatic progenitor cells to develop into functional beta cells (the cells destroyed in type 1 diabetes) that produce and release insulin. When these cells were allowed to clump into three-dimensional structures resembling natural pancreatic islets, they produced significantly more insulin than cells grown in flat cultures. Transplanted into diabetic mice, these structures maintained normal blood sugar levels. This work remains preclinical, but it establishes fetal pancreatic tissue as a viable starting material for generating replacement insulin-producing cells.
Why Fetal Cells Face Fewer Rejection Problems
One practical advantage of fetal stem cells is their reduced tendency to trigger immune rejection. The proteins on cell surfaces that normally alert the immune system to foreign tissue are expressed at much lower levels on fetal cells compared to adult cells. Adult bone marrow transplants require careful tissue-type matching between donor and recipient and carry a real risk of graft-versus-host disease, where transplanted immune cells attack the recipient’s body. Fetal stem cells largely sidestep this problem.
That said, immune suppression drugs are still likely necessary for most fetal stem cell therapies, at least in the near term. One proposed solution is building banks of fetal stem cell lines covering a wide range of tissue types, increasing the odds of a close match for any given patient.
The Shifting Regulatory Landscape
Research involving fetal stem cells, particularly those derived from elective abortions, faces significant political and regulatory headwinds. The NIH announced a major policy shift ending all funding for research using human fetal tissue from elective abortions. The policy applies across both internal NIH research and all externally funded grants and contracts. NIH-supported fetal tissue research had already been declining since 2019, with only 77 funded projects in fiscal year 2024.
This policy shift has accelerated interest in alternative fetal stem cell sources that don’t carry the same ethical concerns, particularly amniotic fluid and placental tissue collected during routine births. These sources are increasingly viewed as both scientifically viable and politically sustainable, which helps explain why the most active clinical trials, like the CuRe spina bifida trial, use placenta-derived cells rather than aborted fetal tissue.